Auf dieser Website kommen Cookies zum Einsatz. Für weitere Informationen über Cookies, klicken Sie bitte auf den Link Datenschutz. Wenn Sie „Ok“ klicken und die Website weiter nutzen, gehen wir von Ihrem Einverständnis aus.

Cookies are used on this website. For more information about cookies, please click on the Privacy Policy link. If you click on "Ok" and continue to use the website, we assume your agreement.

  • Tafel mit Logos vorm Gebäude

adivo GmbH

AMSilk GmbH
adivo GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON:
FAX:
E-Mail: info@adivo.vet
URL: www.adivo.vet
Details

Pet ownership constantly increases and nowadays people are considering their cat or dog as a member of the family. As pets live longer, they develop similar geriatric and civilization diseases as humans but there is a gap in the availability of innovative and specific treatments for serious diseases or chronic conditions in companion animals.

Our mission is to develop novel, species-specific therapeutic antibodies from our proprietary, and state of the art antibody platform. The whole team is very passionate identifying unmet medical needs and supporting veterinary health professionals as well as pet owners in treating dogs & cats with novel highly efficient drugs. 

Antibody selection is based on a novel fully synthetic and species-specific phage display technology. Currently used strategies rely on the modification of a single existing molecule in a process that is laborious and prone to failure.  Our platform allows the de-novo identification of a panel of antibodies to select the best in class drug candidate with optimal functionality, developability and low risk of immunogenicity. Our primary goal is to address the medical need in canines, but the technology will be adapted at later stages to other species such as cats or horses.

In addition to our own drug development, we are planning collaborations with pharmaceutical partners from the veterinary field.

AMSilk GmbH

AMSilk GmbH
AMSilk GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/579 53 93-0
FAX: +49 (0)89/579 53 93-30
E-Mail: info@amsilk.com
URL: www.amsilk.com
Details

AMSilk is a privately-held company that develops, manufactures and markets innovative cosmetic ingredients, novel applications and coatings for medical technology products as well as technical fibers on a worldwide basis.

 

Functional silk is biocompatible and can be used in various applications, for example in specialized coatings and other products in medical technology. Like most biopolymers, silk has evolved over millions of years resulting in a combination of properties that far exceed any man-made material. AMSilk has developed a proprietary process for producing this unique biopolymer and is the leader in the subsequent production and processing of the material.

Avergen Pharmaceuticals GmbH (APG)

Avergen Pharmaceuticals GmbH (APG)
Avergen Pharmaceuticals GmbH
Am Klopferspitz 19
Postfach 68
82152 Planegg/Martinsried
Germany
FON: +49 (0)89/23 51 33 67
MOBIL: +49 (0)172 416 24 04
FAX:
E-Mail:
URL: www.avergen.com
Details

Avergen Pharmaceutical GmbH (APG) was founded 2015 in Munich, Germany. APG is dedicated on innovative novel drug targets in its core competence area in CNS diseases. APG is focusing on the development of new drug candidates until phase II clinical studies. Academic and biotech collaborations will assist APG in its early stage drug discovery activities. APG’s long term objective is to enter into licensing agreements with major biotech or pharmaceutical companies and to clinically develop, manufacture and market its key assets. A complete vertical integration of the value chain is not planned.

ARS3 Pharma Management GmbH & Co. KG

Avergen Pharmaceuticals GmbH (APG)
ARS3 Pharma Management GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried
Germany
FON: +49 (0)89/215 400 420
E-Mail: info@ars3pm.com
URL: www.ars3pm.com
Details

ARS3 Pharma Management provides consulting and interim management services to the healthcare sector. The three founders Dr. rer. nat. Andreas Heuser, Dr. med. Rainer Uhlenbusch und Dr. med. Stefan Ullrich have worked in R&D, medical affairs, marketing, sales and business development. In addition, they have built and lead organizations within big pharma, mid-size companies and the biotech sector. ARS3 offers a range of project-related activities, legal representation and strategic/senior management support. One focus is on medical-scientific issues.

Bayerische Gewebebank

Atres Group
Bayerische Gewebebank GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/70 95 37 00
E-Mail: BayerischeGewebebank@arcor.de

Bernina Plus GmbH

Bernina Plus GmbH
Bernina Plus GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland

E-Mail: gropp@berninaplus.de

Bicoll GmbH

Bicoll GmbH
Bicoll GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/82 07 25 64
FAX: +49 (0)89/529 178
E-Mail: info@bicoll-group.com
URL: www.bicoll-group.com
Details

Bicoll technology allows the fastest approach from initial screening to access the first animal data with small active molecules within a short nine month time period (http://bit.ly/1WDGb0m). This can also be achieved under difficult medicinal settings (e.g. orphan targets, rare diseases) as well as in the fields of crop protection, food supplements and cosmetics.
Bicoll chemical starting points for drug development have a proven higher chance to survive the early research phase to achieve the product. Bicoll has an interest in finding potential partners who have the expertise to identify appropriate biological pathways that can map diseases, but who do not possess any relevant active molecules for targeted intervention in this particular field.
Bicoll is an internationally acting company, working in successful cooperations with global partners such as GENFIT, Bayer, EpimiRNA.

BioM Biotech Cluster Development GmbH

BioM Biotech Cluster Development GmbH
BioM Biotech Cluster Development GmbH
Am Klopferspitz 19a
IZB-West
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/89 96 79-0
FAX: +49 (0)89/89 96 79-79
E-Mail: info@bio-m.org
URL: http://www.bio-m.org

BioNTech Small Molecules GmbH

BioM Biotech Cluster Development GmbH
BioNTech Small Molecules GmbH
Am Klopferspitz 19a
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/818 8802-0
FAX: +49 (0)89/6131 9084-390
E-Mail: info@biontech.de
URL: www.biontech.de
Details

Research:  BioNTech Small Molecules GmbH (BNSM) is focused on the identification, characterization and development of novel innovative small molecule compounds to be used as cancer therapeutics, especially in the field of immune oncology. Several of the drug candidates discovered in recent years have been developed through regulatory preclinics into clinical phases. BNSM contains all important research units to maintain a sustainable project pipeline: computer based hit finding and lead optimization, medicinal chemistry, chem- and bioanalytics as well as formulation development. To ensure a complete characterization of drug candidates, we perform also pharmacokinetic and toxicological studies in house. Our activities are supported by a broad network of biologists and pharmacologists.

Services:  BNSM, a 100% subsidiary of BioNTech AG, offers services throughout the complete discovery process. These drug discovery services encompass all research areas from the identification of initial hits to the selection of the preclinical drug development candidate. Special expertise can be provided in the fields of computational chemistry, medicinal chemistry, analytics, pharmacology and pharmacokinetics/toxicology.

CANKADO Service GmbH

CANKADO Service GmbH
CANKADO Service GmbH 
Am Klopferspitz 19a
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/998 27 1772
E-Mail: info@cankado.com
URL: www.cankado.com
Details

CANKADO is a digital diary for dynamic therapy support and intelligent symptom monitoring in chronic diseases and widely used in oncology (www.cankado.com). Physicians can apply CANKADO in the routine, but also for research projects, clinical trials and quality assurance measures.

CANKADO is financed by research projects, drug-specific support programs and clinical trials. The eHealth platform is free for patients and physicians and can be used on the PC, tablet or via the APP. Data privacy is of high importance. Thus, the data belongs to the patient and is not forwarded, except for clinical trials.

As multilingual platform, CANKADO is meanwhile used from Russia to Australia. Additionally to Martinsried, CANKADO is located in Cologne, Boston (USA), Trivandrum and Kochi (India).

CEM Chemieschule Dr. Erwin Elhardt

CEM Chemieschule Dr. Erwin Elhardt
CEM Chemieschule Dr. Erwin Elhardt
Am Klopferspitz 19a
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/65 14 031
FAX: +49 (0)89/65 14 033
E-Mail: info@chemieschule-bayern.de
URL: www.chemieschule-bayern.de
Details

Training center for chemistry, biology and environment – BTA formation at IZB Martinsried

The Dr. Erwin Elhardt School of Chemistry, located in the training center for chemistry, biology and environment, is the oldest private school in Munich with more than 120 years of experience in the area of scientific technological training. State-approved chemical-technical assistants (CTAs), biotechnical assistants (BTAs) and chemical techniciens are trained here.

From September 2010, the training of the BTAs will be transferred to the new building of the IZB Innovation and Startup Center for Biotechnology in Martinsried where modern laboratories with state of the art equipment are available - tailor-made for this training. Here, the practical and theoretical instruction can be given in close proximity to the numerous life science companies.

ChromoTek GmbH

ChromoTek GmbH
ChromoTek GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/12 41 48 80
FAX: +49 (0)89/12 41 48 811
E-Mail: info@chromotek.com
URL: www.chromotek.com
Details

ChromoTek GmbH, founded in 2008, is a biotech company focused on the discovery and development of novel nanoprobes and cell based assays for biomedical research and early drug development. During the last years ChromoTek has developed innovative research tools including the GFP-Trap® and RFP-Trap®, two versatile pull-down reagents for biochemical analysis of fluorescent fusion proteins. In April 2011 ChromoTek successfully introduced its first cell based assay for early drug development, the U2OS Cell Cycle Chromobody®. This real-time High-Content Analysis (HCA) screening assay enables to monitor the complete cell cycle in live cells for the first time. In addition ChromoTek developed the Fluorescent 2-Hybrid (F2H)-Assay to analyze protein-protein interactions in vivo in real time.

Crelux GmbH

Crelux GmbH
Crelux GmbH
Am Klopferspitz 19a
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/700 76 01 70
FAX: +49 (0)89/700 76 02 22
E-Mail: schaeffer@crelux.com
URL:www.crelux.com
Details

CRELUX specializes in tailor made protein crystallography services. Our high success rates are based on a state-of-the-art technology platform, innovative expression systems and a supreme crystallography expertise.

We have solved hundreds of complex structures for Pharma and biotech companies worldwide, and are focussing to advance innovations in protein expression to promote the availability of high quality crystallizable protein.

Our Off-the-Shelf portfolio of readily available proteins focuses on therapeutically relevant targets. Co-crystal structures of these targets in complex with customer compounds are delivered at affordable rates within weeks.

Protein crystallography services from cloning to high resolution complex structure are provided through custom designed projects under individual agreements following our customer’s needs.

Through our partnership with GVKBio in India we are offering end-to-end drug discovery services, including fragment based approaches.

DPC Pharma Consulting | BioMedPartners Venture Partner

DPC Pharma Consulting | BioMedPartners Venture Partner
DPC Pharma Consulting | BioMedPartners Venture Partner
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/550 54 75-10
FAX: +49 (0)89/550 54 75-21
E-Mail: info@dpcpharma.de
URL:www.dpcpharma.de
Details

Recognizing the bearing capacity of an idea: from the solid scientific result to the feasibility of the product

DPC Pharma Consulting was founded in 2007 by Dr. Karl Deres with offices in the IZB Martinsried Biotech Centre and in Berlin City. DPC Pharma Consulting is an advisory company offering services in the pharmaceutical/biotech industry, including interim management in the fields of business & strategic corporate development, clinical & regulatory aspects as well as R&D management. The main emphasis results from the core competence drug development in the area of chronic inflammatory diseases like auto-immune disorders and cancer. As a venture partner of the BiomedPartners, Dr. Karl Deres also supports their representation in Munich. The effectiveness of DPC Pharma Consulting lies in its ability to value and appreciate people and thereby to inspire people: when performance is recognized, the willingness to perform increases; those who have the courage to find differences, help to make the difference.

Dust BioSolutions GmbH

http://www.dustbiosolutions.com
Dust BioSolutions GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/41 85 67 31
E-Mail: info@dustbiosolutions.com
URL: www.dustbiosolutions.com

EllaBiotech GmbH

EllaBiotech GmbH
EllaBiotech GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/70 93 93 16
FAX: +49 (0)89/70 93 94 40
E-Mail: info@ellabiotech.com
URL www.ellabiotech.com
Details

ELLA is an independent, privately owned company founded in October 2004.

ELLA offers creative services for the production of high quality special oligonucleotides for selected projects in diagnostics, chip technologies and further topics - following quality standards which you would appreciate and expect in your own lab.

ELLA´s vision is the closest cooperation with our customers, such that the external oligonucleotide synthesis unit at Ella Biotech operates like an outsourced in-house production of the particular company.

The guidelines for the synthesis standards are defined by our customers themselves after intensive consultation. Before production commences, we fully work up this list of requirements based on our customers production standards

Evotec Munich

Evotec Munich
Evotec Munich
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/452 44 65-0
FAX: +49 (0)89/452 44 65-220
E-Mail: proteomics@evotec.com
URL: www.evotec.com
Details

Chemical proteomics and phosphoproteomics applications

Evotec Munich is an affiliate of Evotec AG and based in Munich/Martinsried, Germany.

Evotec Munich is a service company specializing in chemical proteomics and quantitative phosphoproteomics methods to support the successful development of small molecule drugs.

Evotec Munich delivers a comprehensive analysis of a compound‘s mode of action in a cell. This significantly supports decision making at various stages of the drug discovery process, such as lead optimization or clinical trial candidate selection, reduces development times and predicts a drug‘s therapeutic outcome.

Exosome Diagnostics Inc.

Exosome Diagnostics Inc.
Exosome Diagnostics Inc.
Am Klopferspitz 19a
82152 Planegg/Martinsried
Deutschland
FON:
FAX:
E-Mail: mikkel@exosomedx.com
URL: www.exosomedx.com
Details

The US company founded by biotech entrepreneurs James McCullough and Wayne Comper in 2008 to develop body fluid molecular diagnostics based on discoveries made by researchers at Harvard University and Massachusetts General Hospital. The company holds an exclusive worldwide licence to the fundamental intellectual property from Massachusetts General Hospital.

Exosomes and other microvesicles are constantly shed from many cell types in the body, even under normal conditions, but even more so from cancer cells, and they end up in body fluids, including blood and urine. Exosome Diagnostics isolates exosomes from serum, plasma, urine or other bodily fluids, extracts the RNA, which is stable even in biobanked samples, and develops and performs minimally invasive, molecular diagnostic assays on this exoRNA, for example for known cancer biomarkers. The ability to detect and genotype nucleic acids of tumour origin from a blood draw or a urine sample without the need for a biopsy or surgically resected tissue has a number of unique advantages, for example when tissue is difficult or impossible to access, and it opens up several new opportunities such as disease monitoring, tumour recurrence monitoring or other longitudinal studies.

According to the company's Director of European Operations, Dr Mikkel Noerholm, opening a German subsidiary as the centre of Exosome Diagnostics' European presence is an important part of the company's business plan and strategy. Its headquarters are located on the Columbia University Medical Campus in Manhattan, New York, and house the company's primary R&D laboratories. The company's other US site in Minnesota serves as the clinical development laboratory. The site in IZB Martinsried will serve as the point of contact for European collaborations and receipt of clinical samples from partners in Europe. The site will initially house the company's primary bioinformatics research capabilities and, as it moves into laboratories in IZB in 2011, Exosome will add wet-lab capabilities to become a fully functional sample processing and research operation.

FROST LIFESCIENCE

FROST LIFESCIENCE
FROST LIFESCIENCE
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/517 77-140
FAX: +49 (0)89/517 77-160
E-Mail: info@frost-lifescience.com
URL: www.frost-lifescience.com
Details

FROST LIFESCIENCE
Provides Life Science and Biotech Start Up- Companies support in Business Development, Marketing and Sales.

For Start Up-Companies it is eminently important to enter the market as early as possible. We`ll support you to develop your technologies and products together with your potential customers. This will help you to be one step ahead and thus lead you to successful business.
Services:
Business Development
Marketing
Sales
Coaching

FROST LIFESCIENCE is a specialist for human Primary Cells, human Stem Cells, Stem Cell Assays, 3D in vitro Assays (Skin, Angiogenesis, Tumor models), Cell based Assays and viral Gene Transfer .

GENidee

GENidee
GENidee
Lise-Meitner-Str. 30
85354 Freising/Weihenstephan
Deutschland
FON: +49 (0)8161/80 68 186
FAX: +49 (0)8161/80 68 185
E-Mail: info@genidee.eu
URL: www.genidee.eu
Details

GENidee is a young and innovative biotech company specialized in the development, production and marketing of molecular-biological diagnostic kits for the rapid detection of food-borne pathogens as well as microbial contaminants in food. Fast and reliable PCR diagnostics is guarantied by a parallel analytics suited to the individual customer requirements. GENidee offers molecular-biological service of highest quality. Using our kits directly in the production facilities enables the results of microbiological analytics to be supplied much sooner than by conventional diagnostics. The individual care of our customers and the consequent customer satisfaction is our top prioriy.

gimbio mbH

gimbio mbH
gimbio mbH
Lise-Meitner-Str. 30
85354 Freising/Weihenstephan
Deutschland
FON: +49 (0)8161/986 44 80
FAX: +49 (0)8161/986 56 61
E-Mail: info@gimbio.de
URL:www.gimbio.de
Details

gesellschaft = Society for
information
management in the
biotechnology
Gimbio - Society (=Gesellschaft)for Information Management in the Biotechnology

sees itself as a company that provides innovative products and solutions in the bio process technology, especially for undertakings in the range of food, brewing or biotechnology industry.

The basic idea of the enterprise is, beside the acquisition of information and - processing, the development and application of innovative online measuring systems for biotechnological process condition sizes for the purpose of process Design, modelling and simulation with the ultimate goal of the optimization of underlying bio processes.

Gimbio moves in the bioprocess-technical market segment. This includes pharmaceutical manufacturers as well as like food-processing enterprises. In particular applications from the brewing industries are as example processes in the focus of interest. (End) product manufacturer and plant designers as well as system developers benefit from the firm offer at the same time.

Innovation is not only a key word for us, but the engine of conversion and the spirit of enterprise. We will not rest ourselves at the innovation from yesterday, but - also in a scientific context - tempt to participate the innovations of tomorrow that are engaged in our sphere of competence.

The special competence of gimbio is to apply mathematical and information-technical methods effectively and problem-consciously out of a profound bio procedural process understandingand and of course in a maximum possible customer orientation.

We offer custom-made solutions to you. On the one hand by our product range, which we adapt gladly on your needs. On the other hand we see ourselves as a customer-oriented service provider, that compiles special developments for your courses of business.

We strive for constructive cooperation with our customers in a reciprocal win-win siutation with an increase in knowledge, expertise and experience.

We do not only speak of partners and customer orientation, but want to transcribe it discreetly and engaged. Since we have our roots ourselves in the bio and food process engineering, we speak the language of our customers, thus we do not only understand their problems superficially and can provide problem-consciously effective solutions.

GNA Biosolutions GmbH

GNA Biosolutions GmbH
GNA Biosolutions GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/99 82 07 180
FAX: +49 (0)89/99 82 07 188
E-Mail: info@gna-bio.de
URL: www.gna-bio.de
Details

GNA Biosolutions is developing a pipeline of diagnostic instruments and assays for robust, ultra-fast detection of important human pathogens based on its proprietary Laser PCR technology. The world’s fastest thermal cycles for DNA amplification and detection can be achieved by ultra-fast laser-heating of nanoparticles within the sample solution, an optothermal technology that allows heating and cooling rates many orders of magnitude faster than other PCR methods. The localized nano heating technology is combined with fluorescent-free DNA detection, making ultra-fast DNA-based tests possible within 15 minutes or less. GNA Biosolutions has designed and manufactured the Pharos400 instrument that works with 8-plex test cartridges offering a simple and cost-effective detection of multi-resistant pathogens like MRSA or viruses at point-of-care.
GNA Biosolutions GmbH was spun-out of the Institute for Photonics and Optoelectronics at Ludwig-Maximilians-Universität, Munich, in 2010, and is located in the Innovation and Start-Up Center for Biotechnology (‘IZB’) in Martinsried near Munich. For more information please visit our website: www.gna.bio

Industrielle Biotechnologie Bayern Netzwerk GmbH

Industrielle Biotechnologie Bayern Netzwerk GmbH
Industrielle Biotechnologie Bayern Netzwerk GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/540 45 47 - 0
FAX: +49 (0)89/540 45 47 - 15
E-Mail: info@ibbnetzwerk-gmbh.com
URL: www.ibbnetzwerk-gmbh.com
Details

Industrielle Biotechnologie Bayern Netzwerk GmbH (IBB Netzwerk GmbH) is an organization focusing on the promotion of real economy with the aim of transforming valuable scientific knowledge in the area of industrial biotechnology to innovative marketable products and processes. One of the main tasks of IBB Netzwerk GmbH is the management and coordination of the network IBB. Within this network, the competences and the potentials of industry, small and medium enterprises, academia, business developers, consultants and associations are combined and mobilized to strengthen as well as to expand industrial biotechnology.

Services:
IBB Netzwerk GmbH...

  • conducts technology scouting und market monitoring
  • identifies suitable project partners
  • connects companies and academia across sectors
  • organizes meetings for members of the network
  • initiates and accompanies research and development projects
  • builds the interface to appropriate financial sources and granting agencies
  • performs administrative project management
  • promotes and accompanies spin-offs and start-ups as well as the settlement of companies
  • initiates commercial transactions and deals
  • fills slots of conferences and meetings with network members
  • presents the concept and the achievements of the network in congresses and trade fairs
  • provides the network and public with prepared relevant information
  • arranges events for professionals and general public
  • abets the dialogue with politicians by organizing parliamentary evenings, workshops and plant visits

ibidi GmbH

ibidi GmbH
ibidi GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: + 49 (0)89/520 46 17-0
FAX: + 49 (0)89/520 46 17-59
E-Mail: info@ibidi.de
URL: www.ibidi.de
Details

cells in focus

ibidi is a system provider for microscopy based functional cell-based assays. ibidi develops, produces and distributes cell-culture biochips (µ-Slides) and complete solutions for functional cell-based assays. An extensive line of µ-Slides and µ-Dishes offers solutions for immunofluorescence and basic cell culture, plus the following complex assays: angiogenesis, chemotaxis, wound healing, shear stress and flow.

The company also specializes in instruments such as heating and incubation units, and a unique perfusion system that provides continuous flow for the simulation of blood vessels. All of ibidi’s products are designed with high end microscopy in mind.

The high optical quality of the μ-Slides allows microscopic cell investigations, using phase contrast or DIC, fluorescence and also confocal microscopy. The new F-actin marker LifeAct makes it possible to keep track of the development and movement of F-actin structures in living cells. More than 800 publications document the successful use of ibidi’s technologies.

In Germany, ibidi works with its own sales team. In all other countries, ibidi products are offered through a variety of distributors.

Immunic AG

Immunic AG
Immunic AG
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89 250079460
FAX: +49 (0)89 250079466
E-Mail: info@immunic.de
URL: www.immunic-therapeutics.com
Details

Immunic AG is a start-up biotech company founded in April 2016 and focused on the development of orally available, small molecule immune modulators to block immune and autoimmune responses. Immunic develops drug candidates until clinical proof of concept. Immunic, with headquarters in Planegg-Martinsried near Munich, Germany, is privately held and supported by several renowned sector investors.

Kindermedizin.info UG

Kindermedizin.info UG
Kindermedizin.info UG
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: + 49 (0)89/99 52 92 22
MOBIL: + 49 (0)160/97 77 58 89
E-Mail: B.Sonntag@kindermedizin.info
URL: www.kindermedizin.info
Details

Kindermedizin.info is an internet portal aiming at improving the quality of information regarding Pediatrics. Parents and other interested parties should be protected from misleading information on children's health and hence be better informed on the basis of current, scientifically backed up content.

LEUKOCARE AG

LEUKOCARE AG
LEUKOCARE AG
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/780 16 65–0
FAX: +49 (0)89/780 16 65–11
E-Mail: info@leukocare.com
URL: www.leukocare.com
Details

LEUKOCARE is a privately owned, product-focused, clinical-stage biotechnology company founded in 2003. In 2010, LEUKOCARE has relocated its headquarters and R&D facilities to the IZB in Martinsried near Munich, Germany.

LEUKOCARE develops innovative life science technologies in the fields of biopharmaceuticals, drug device combination products, biochemical research products and diagnostic assays.

LEUKOCARE’s Stabilizing and Protecting Solution (SPS) allows to extend shelf life of biologics in dehydrated state and to retain functionality during sterilization by gamma-, beta-radiation or ethylene oxide. LEUKOCARE’s technologies thus enable the design of a new range of products that would not be amenable otherwise, reduce costs, simplify production, and ease regulatory issues.

LEUKOCARE also has expertise in functionalizing a wide variety of surfaces including implant surfaces, wound dressings, patches, stents, catheters, columns for ex-vivo blood treatment and others. LEUKOCARE offers collaborative research and development services with biological and chemical lab capacity to interested partners related to its core competences. LEUKOCARE’s portfolio of patented technologies is available for purchase, licensing or collaborative product development customizing the SPS technologies to the requirements and needs of interested partners.In order to ensure both consistent high quality of its products and services and to comply with ISO standards, LEUKOCARE implemented a Quality Management System and is certified according to DIN EN ISO 9001:2008 and DIN EN ISO 13485:2003.

Menlo Systems GmbH

Menlo Systems GmbH
Menlo Systems GmbH
Am Klopferspitz 19a
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/18 91 66 0
FAX: +49 (0)89/18 91 66 111
E-Mail: webmaster@menlosystems.com
URL: www.menlosystems.com
Details

Counting with the heartbeat of light - Precision made in Germany

Menlo Systems GmbH, Am Klopferspitz 19, D-82152 Martinsried

The eye muscle is the fastest muscle in the human body, closing in milliseconds. One would think of it as quick as lightning. However, compared to the shortest time segments in modern daily life it is nearly an eternity. We are facing this challenge with our patented frequency comb technology. The technology - simply put - makes it possible for the first time ever to measure the entire spectrum of light in the visible and near infrared. Based on the technology we have developed a series of instruments over the last years that allow for finer and finer measurements. The pride and joy of Menlo Systems is the "optical frequency synthesizer". With the portable instrument, light frequencies can be measured with a precision of up to 15 digits beyond the decimal point. This allows our customers to measure time more precisely than ever - a thousand times more precisely than the Cesium atomic clock, until now regarded as the non-plus-ultra in capturing time.

MetaHeps GmbH

MetaHeps GmbH
MetaHeps GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/70076625
MOBILE: +49 (0)151 17997111
E-Mail: abenesic@metaheps.com
URL: www.metaheps.com
Details

MetaHeps GmbH is a spin-off company of the LMU Munich and develops the first in vitro test (MetaHeps® Test) to diagnose and exclude idiosyncratic drug-induced liver injury (iDILI).

iDILI is an important reason for acute liver failure and also a huge risk in clinical drug development: iDILI affect only susceptible patients (e.g. 1 in 10.000) while most of patients can be treated without developing liver damage. There is no clear dose-relationship and the latency of iDILI varies between weeks and months. The importance of the individual patient characteristics for the occurrence of iDILI precludes detection in preclinical (cell or animal) models. Therefore, iDILI is often only detected in late stage clinical trials potentially leading to project terminations or even withdrawals with huge financial losses. There is also relevant damage to patients: the susceptibles, who potentially develop life-threatening liver failure, but also the tolerators who may loose an important treatment option to withdrawals or terminations.

Despite this impact of iDILI for drug development iDILI diagnosis is mainly based on exclusion of other etiologies of liver damage (e.g. viral hepatitis) and gold standard for causality assessment is expert opinion. In patients taking several drugs it may be impossible to identify the causative agent.

The MetaHeps® test is offered as a service for Pharma and CROs: Using a blood sample from patients with iDILI suspicion the test can a) clear a drug from iDILI suspicion, b) identify potentially dangerous interactions that can be avoided in future and c) identify true positive cases for a given drug and thus facilitate the development of innovative and specific safety biomarkers. This will improve patient safety as well as reduce incorrect stops in drug development.

Omegametrix GmbH

Omegametrix GmbH
Omegametrix GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/55 06 30 0
FAX: +49 (0)89/55 06 30 08
E-Mail: info@omegametrix.eu
URL: www.omegametrix.eu
Details

A low omega-3 index is a significant risk factor towards heart attack (acute myocardial infarction). To know ones omega-3 index can help calculate this risk. The right alimentation/ fish oil supplementation can increase the index. Omegametrix GmbH, a international reference laboratory, measures the omega-3 index in a standardised way.
 

origenis gmbh

origenis gmbh
origenis gmbh
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/780 16 76 0
FAX: +49 (0)89/780 16 76 777
E-Mail: info@origenis.de
URL: www.origenis.de
Details

Origenis offers creative services for drug design, synthesis, and characterisation driven by its patented technology platform MOREsystem®.

Origenis creates novel target-focused and indication-optimised pre-clinical compound families and the related IP to its customers.

The origenis system integrates essential Pharma concepts in a novel process. This unique approach is more systematic and 200 times faster.
 

PELOBIOTECH Gmbh

PELOBIOTECH Gmbh
PELOBIOTECH Gmbh
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/51 72 86 59-0
FAX: +49 (0)89/51 72 86 59-88
E-Mail: info@pelobiotech.com
URL: www.pelobiotech.com
Details

PELOBIOTECH GmbH develops and produces special cell culture media for human primary cells and stem cells as well as special supplements for tumor stem cells. It is our goal to develop media systems which are animal-free and/or defined to make the usage of animal components (e.g. FBS, BSA, BPE) redundant. Our media systems are developed to work with both commercially available cell systems as well as with from tissues isolated cells.

In addition to our media products, PELOBIOTECH GmbH distributes a broad range of cell culture products from our exclusive partners worldwide. We are very keen to offer the broadest portfolio of human and animal primary cells as well as stem cells:

  • Human/animal primary cells & stem cells
  • iPS derived cells & iPS media
  • Modified and tagged primary cells & stem cells
  • 3D Cell Culture Technology (Scaffolds, Hydrogels, Scaffold--free)
  • 3D Microtissues ready-to-use
  • Angiogenesis Models and Angiogenesis validated Primary cells
  • MicroMatrix Array for the optimal cell/stem cell microenvironment (ECM and soft underground)
  • Cell Culture Tools – Cytokines, Growth Factors, Chemokines, Biomatrix Proteins, Purification Systems for DNA/RNA/Proteins, Dyes for Microscopy, FACS and HTS, thousands of Elisa KITs and Antibodies
  • Instruments: µ Volume Spectrophotometer & Automatic Cell Counter

Together with our new partners Akron biotech, irisbiosciences, BioLifeSolutions and Helios BioScience we are now able to offer GMP products from tissues dissociation to cryopreservation (e.g.: cytokines, growth factors, biomatrix (ECM) proteins, cryopreservation media, scaffolds, hydrogels, cell culture supplements (AB serum, BSA) and platelet lysate).

Services are offered via our excellent partners GenXPro (Transcriptomics, Genomics, Epigenomics, Bioinformatics), irisbiosciences (Contract Manufacturing of adipose derived cells), ReachBio Research Labs (Hemotoxicity Testing, Cancer Stem Cell and Leukemic CFC Assays, Cytokine Storm Risk Analysis and Stem Cell Mobilization Assays and PELOBIOTECH (development & production of cell culture media and customized cell isolation).

PhaToCon (Pharm/Tox Concept)

PhaToCon (Pharm/Tox Concept)
PhaToCon (Pharm/Tox Concept)
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/44 48 99 41
FAX: +49 (0)89/44 48 99 43
E-Mail: info@phatocon.com
URL: www.phatocon.com
Details

preclinical pharmacology / toxicology hands-on consulting

Pieris AG

Pieris AG
Pieris AG
Lise-Meitner-Straße 30
85354 Freising/Weihenstephan
Deutschland
FON: +49 (0)8161/141 14-00
FAX: +49 (0)8161/141 14-44
E-Mail: info@pieris-ag.com
URL: www.pieris-ag.com
Details

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins for the diagnosis and treatment of life-threatening human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its Anticalin candidates. Recognizing the enormous market potential of protein-based drugs, Pieris is committed to becoming an integrated drug discovery and development company and expects to file an IND application for its first therapeutic Anticalin at the beginning of 2008. 

PreOmics GmbH

PreOmics GmbH
PreOmics GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0) 89/23 14 163 - 0
FAX: +49 (0) 89/23 14 163 - 99
E-Mail: info@preomics.com
URL: www.preomics.com
Details

The PreOmics GmbH develops and commercializes tools for mass spectrometry-based proteomics. The main focus are easy and optimized sample preparation methods enabling fast, efficient and sensitive measurements at high throughput. PreOmics further develops instruments for automated fractionation and enrichment to achieve complete proteomics and to facilitate the analysis of signal-transduction pathways. PreOmics addresses customers in research, drug development and diagnostics.

Rigontec GmbH

Rigontec GmbH
Rigontec GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)228/76 37 01-11
FAX: +49 (0)175/94 90 287
E-Mail: info@rigontec.com
URL: www.rigontec.de
Details

Rigontec GmbH is a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.
The key technology of Rigontec is a proprietary platform delivering synthetic ligands of a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I), whose function in nature is to recognise viral RNA. Appropriate activation of RIG-I promotes the initiation of an immunogenic cell death of diseased cells, making the tumour microenvironment foster anti-tumour immunity, and thereby establishing long-lasting systemic immune memory. Rigontec’s technology has the potential to treat and prevent recurrence of disease.
Rigontec’s lead compound RGT100, a proprietary first in-class drug candidate selectively targeting RIG-I with high specifi city, is in late stage preclinical developmentand will first be evaluated in the clinic for several cancer
types.
Rigontec’s platform technology also offers the opportunity to develop antiviral therapeutics and allows the design of pipeline candidates with additional gene silencing and inhibitory activities further broadening the applicability of this groundbreaking new class of drugs in the area of oncology and viral infections.
Rigontec was launched in January 2014 as a spinout of the Institute for Clinical Chemistry and Clinical Pharmacology at the University Hospital of the University of Bonn, Germany.
The company has raised €14.25 million in its recent Series A fi nancing round and is operating at two locations in Bonn and in Munich, both in Germany.
Rigontec is supported by a consortium of experienced Life Science investors including Wellington Partners, Boehringer Ingelheim Venture Fund, NRW.BANK, High-Tech Gründerfonds (HTGF), Forbion Capital Partners and Sunstone Capital.


SciMab GmbH

SciMab GmbH
SciMab GmbH
Am Klopferspitz 19
82152 Planegg-Martinsried
FON: +49 (0)89/614241230
FAX:  +49 (0)89/614241240
E-Mail: info@scimab.com
URL: www.scimab.com
Details

Founded in late 2016, SciMab is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threating diseases.

Secarna GmbH & Co. KG

SciMab GmbH
Secarna GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg-Martinsried
FON: +49 (0)89/21546375
FAX: +49 (0)6421//98300599
E-Mail: info@secarna.com
URL: www.secarna.com
Details

Secarna is a new breed biopharmaceutical company based in Munich, Germany, We have developed a proprietary drug discovery platform, LNAplus™, for the next generation of antisense oligonucleotides.

Together with our partners in academia and industry, we are developing multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immuno-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and for anti-viral applications. For more information, please visit www.secarna.com.

SIRION Biotech GmbH

SIRION Biotech GmbH
SIRION Biotech GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/70 09 61 999
FAX: +49 (0)89/70 09 61 998
E-Mail: info@sirion-biotech.de
URL: www.sirion-biotech.de
Details

State of the art service provider for preclinical target research

SIRION Biotech GmbH has been operating for 7 years as a specialized service provider for preclinical target research. Using proprietary viral vector (AV, LV and AAV) and RNAi technologies SIRION`s customized assay cell models offer access to in depth functional gene analysis, thereby improving target identification/ validation and compound screening in a variety of industries. Their technologies have also been successfully used for primary cell immortalizations. Moreover, novel viral vectors for gene therapy and vaccine applications are under development.

SpheroTec GmbH

SpheroTec GmbH
SpheroTec GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/70 95-6438
FAX: +49 (0)89/70 95-6263
E-Mail: info@spherotec.com
URL: www.spherotec.com
Details

SpheroTec means Spherotechnology. Spheroids are miniature tumors in vitro mimicking microtumors in cancer patients. The three-dimensional tissue like model allows predictive drug testing with respect to efficacy, cell toxicity, drug penetration into the microtumor and pharmakodynamic in a very early preclinical phase of drug development. The advantages are obvious: early identification of ineffective and highly toxic drugs, effective selection of therapeutically relevant drugs, high probability of success in advanced clinical trials and thus FDA approval as well as reduction of animal experiments, time and costs. The Spherotechnology is appropriate for all kind of drugs including antibodies and small molecules.

that's it gmbh

that's it gmbh
that's it gmbh
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/124 13 94-0
FAX: +49 (0)89/124 13 94-44
E-Mail: welcome@thatsit-gmbh.de
URL: www.thatsit-gmbh.de
Details

that's it as a system vendor supplies support in any field of computing.

Main focus are server based computing, open source projects and system security as well as high availability solutions, global access, consulting and data recovery. services include project planning, implementation with ongoing support and training.

Thermosome GmbH

Thermosome GmbH
Thermosome GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/716 77 60 31
FAX: +49 (0)89/716 77 60 49
E-Mail: info@thermosome.com
URL: www.thermosome.com
Details

Founded in 2010, Thermosome is a biotech company developing new drug delivery systems for therapeutic and diagnostic agents based on temperature-sensitive liposomes.

The company is using a novel liposome technology based on synthetic phospholipids that provides liposomes with prolonged circulation half-life and ultra-fast release properties. Drug release shall be triggered by the application of energy from an exogenous or endogenous device (e.g. regional hyperthermia, high intensity focused ultrasound) to the patient receiving the treatment. Thermosome will make use of its platform technology in order to not only enhance the efficacy of the drug but also to reduce systemic side effects.

TILL I.D. GmbH

TILL I.D. GmbH
TILL I.D. GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/20 32 41 42-20
FAX: +49 (0)89/20 32 41 42-90
E-Mail: info@till-id.com
URL: www.till-id.com
Details

TILL I.D. GmbH is a small company at the interface of research and industry. We design and develop innovative platform-concepts and opto-electronic modules for light microscopy. Aim is to take the microscope from the 19th into the 21st century by applying a scalable “embedded approach” rather than the usual modular one. Our inspiration is the smartphone, which can be differentiated into a variety of application-specific phenotypes (apps). To underline the versatility of the platform-concept, we call it the “AppMIC”.

TILL I.D. licenses its technologies to partner companies. The revenues, together with funding from the Bundesministerium für Bildung und Forschung (BMBF) and the European Union, allow TILL I.D. to continue its innovative path towards the microscope 2.0.

Trion Research GmbH

Trion Research GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON: +49 (0)89/70 07 66-0
FAX: +49 (0)89/70 07 66-11
E-Mail: mail@trionresearch.de
URL: www.trionresearch.de
Details

TRION Research develops a new class of intact trifunctional antibodies which are specifically targeted at characteristic antigens of tumours. The advantage of these trifunctional antibodies over conventional therapeutic approaches is the fact that they simultaneously activate two immunological cascades and are thus particularly effective in destroying tumour cells.

Umwelt-Geräte-Technik GmbH

Umwelt-Geräte-Technik GmbH
Umwelt-Geräte-Technik GmbH
Lise-Meitner-Str. 30
85354 Freising/Weihenstephan
Deutschland
FON: +49 (0)8161/23 46 441
FAX: +49 (0)8161/23 46 443
E-Mail: info-sued@ugt-online.de
URL: www.ugt-online.de
Details

The Umwelt-Geräte-Technik GmbH (UGT GmbH) is a medium enterprise, which operates successful in the field of environmental monitoring and measuring technologies for 16 years.

According to the company profile, the UGT GmbH develops, produce and distribute measurement and diagnostic tools for soil-water-air-analytics and modules for the environmental monitoring. The installation of complex soil hydrologic and meteorological measuring stations in agriculture, forest and water ecosystems is in the area of operation, as well as the installation of control stations at landfill and mining sites for remediation.

To meet the requirements of a growing national and international market, the UGT GmbH establishes the branch south in Freising-Weihenstephan, close to important scientific centres.

vertis Biotechnologie AG

vertis Biotechnologie AG
vertis Biotechnologie AG
Lise-Meitner-Str. 30
85354 Freising/Weihenstephan
Deutschland
FON: +49 (0)8161/141-1211
FAX: +49 (0)8161/141-1212
E-Mail: info@vertis-biotech.com
URL: www.vertis-biotech.com
Details

VERTIS is a research-oriented company in the field of functional genomics. We develop DNA-based diagnostic kits for animal and human health care, for plant breeding and plant protection using state-of-the-art cDNA technology. Our aim is to provide tools for rapid identification of candidate genes in resolution down to a single cell.

VERTIS was founded in the year 2000 as a spin-off of the Technische Universität München-Weihenstephan, Germany (Chair of Agronomy and Plant Breeding, Prof. Dr. Gerhard Wenzel). We participate in research projects and offer our innovative platform technology as service.

Development of new drugs and progress in animal and plant breeding strongly relies on the identification of genes expressed in a specific cell or which expression patterns change during disease, drug treatment or environmental exposure (differentially expressed genes). High throughput gene discovery programs produce a substantial amount of redundant information and strategies to reduce redundancy are needed. VERTIS has developed innovative tools for the rapid identification of candidate genes which reduces time and costs for downstream gene analyses. We employ straightforward gene enrichment strategies by removal of non target sequences or equalization of gene representation when looking at whole transcriptomes. The technology is very sensitive and allows the analysis of transcriptomes also when only a small number of cells is available.

More Information about VERTIS
If you are interested in our service please visit our web site at http://www.vertis-biotech.com, send us an email to info@vertis-biotech.com or call the VERTIS office at +49-8161-1411211.

Vesalius Biocapital

Vesalius Biocapital
Vesalius Biocapital
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
FON:
FAX:
E-Mail:
URL: www.vesaliusbiocapital.com
Details

Venture Capital for Life Science companies.

Vesalius focuses on the creation, financing and growth of early-stage life science companies. The managed Vesalius funds invest in areas with a high unmet medical need and a significant profit potential: new therapeutics, cutting-edge medical devices, innovative drug delivery technologies and diagnostic tests with a high utility level. The expertise of the team ranges from extensive operations, business development, R&D, and IP management know-how to corporate governance, M&A, and IPO experience in start-ups and mature life science companies. Furthermore, the individual team members have in-depth technical insights and competitive scouting experience in the life science sector. For more information please see www.vesaliusbiocapital.com.

XL-protein GmbH

XL-protein GmbH
XL-protein GmbH
Lise-Meitner-Straße 30
85354 Freising/Weihenstephan
Deutschland
FON: +49 (0)8161/537 30-90
FAX: +49 (0)8161/537 30-99
E-Mail: info@xl-protein.de
URL: www.xl-protein.de
Details

XL-protein: Improved biopharmaceuticals with extended plasma half-life

XL-protein is a biopharmaceutical company utilizing its proprietary 'PASylation' technology to develop second generation biopharmaceuticals with prolonged plasma half-life. PASylation of therapeutic proteins allows less frequent and lower dosing combined with better tolerability, also opening perspectives for the life cycle management of approved biopharmaceuticals.

'PASylation' - the genetic fusion with conformationally disordered polypeptide sequences composed of the amino acids Pro, Ala, and Ser - provides a superior way to attach a solvated random chain with large hydrodynamic volume to a biologically active protein. Thus, its typically rapid clearance via kidney filtration can be retarded by one to two orders of magnitude while the PAS moiety is biochemically inert and easily degradable.